People’s Daily health client reporter Tan Qixin
According to the latest announcement of the National Health and Medical Commission, on April 5, there were more than 20,000 new local positive infections of the new crown in my country, setting a new high for this round of epidemics. Since March 12th, the number of new local infections in my country has exceeded 1,000 every day, which is also the highest number of new infections since the outbreak of the domestic new crown pneumonia epidemic at the end of 2019.
The reporter found out that the Omicron variant was first imported into Hong Kong, my country on November 27, 2021, and was first imported into Tianjin, my country on December 9. Subsequently, point-like infections occurred in many places. In the past month or so, the wave of infection in Omicron has spread in Jilin, Shanghai and other places.
Staff at the Chinese Center for Disease Control and Prevention to receive a new crown for vaccine production from Zhejiang virus strain. Xinhua News Agency Liu Peicheng/Photo
Boost vaccination to consolidate the “first line of defense” against the virus
“As the most powerful technical means to control infectious diseases, the new crown vaccine is still the most effective measure to deal with the normalized prevention and control of the epidemic.” Zhang Boli, academician of the Chinese Academy of Engineering, was interviewed by a reporter from the People’s Daily Health Client time indicated.
In order to control the spread of various variants and the spread of the new crown pneumonia epidemic, countries are currently actively carrying out large-scale inoculation of the new crown vaccine to consolidate the “first line of defense” against the epidemic. Among them, the United States, the United Kingdom and other countries have taken the lead in implementing the sequential booster immunization strategy with different technical routes.
The reporter found that the data from many countries showed that the absolute protection of Omicron (relative to the protection of unvaccinated people) increased significantly by boosting immunization. On March 9, The New England Journal of Medicine (New England Journal) published real-world research data from Qatar. After 2 doses of Moderna vaccine basic immunization, the third dose of Moderna vaccine was sequentially boosted against Omicron. The relative protection against symptomatic infection was 47.3%. Data from a real-world study in the United Kingdom, also published in the New England Journal, showed that in subjects receiving adenovirus vaccine (AstraZeneca) as primary immunization, booster sequential 1 dose of mRNA vaccine (Pfizer) 2 to 4 weeks after , the absolute protection of the vaccine was 62.4%.
Real-world research data in the United States published in Nature Medicine (a sub-journal of Nature) shows that the absolute protection of 3 doses of mRNA vaccine (Modena) against Omicron infection is 62.5%.
Sequential strengthening of domestic vaccines under development has an outstanding protection rate against Omicron, with an absolute protection rate of 61.35%
According to data from the State Food and Drug Administration, as of now, 5 domestically produced new coronavirus vaccines have been approved for use in China. Including 3 inactivated vaccines produced by Sinopharm Zhongsheng Beijing Company, Sinopharm Zhongsheng Wuhan Company, and Beijing Kexing Zhongwei Company, the type 5 adenovirus vector vaccine produced by Tianjin CanSino Company, and the recombinant new coronavirus vaccine of Zhifei Biology ( CHO cells).
At the same time, there are three domestic vaccines in the critical clinical stage, namely Watson Bio/Aibo Bio’s mRNA vaccine, Clover/CEPI/Dynavax recombinant protein vaccine and Livzon monoclonal vaccine. Anti-coronavirus vaccine V-01. Among them, Livzonumab’s new crown vaccine V-01 has entered the phase III clinical trial stage.
“At present, the basic immunization based on inactivated vaccines has been basically completed in China. Research at home and abroad has shown that sequential booster immunization based on inactivated vaccines is the best way to improve immunity to Omicron and the future. The most powerful measures to protect the effect of other epidemic strains.” On April 5, Dr. Yang Jiaming, executive deputy general manager of Livzon Bio, revealed in an interview with a reporter from the People’s Daily Health Client that Livzon mAb’s new crown vaccine V-01 has recently been completed. The interim master data analysis of the phase III clinical trial was sequentially strengthened, and key data were obtained.
The analysis results of its latest phase III clinical key data show that, on the basis of 2 injections of inactivated vaccine, V-01 has a strong effect on the infection of Omicron with mild and above symptoms after sequential strengthening. The absolute protection (relative to the protection of unvaccinated people) is 61.35%, and it is as high as 71.83% for people with high risk of underlying diseases, which is comparable to that of foreign Pfizer and Moderna mRNA vaccine homologous or heterologous 3-needle booster Compared with the inactivated vaccine, the 3-injection booster effect is outstanding, and the adverse reaction rate is low (comparable to the placebo group). It is currently the only protective phase III clinical data. vaccination.
When will the V-01 sequential booster vaccine be available in China? “We have submitted the V-01 Sequentially Strengthened Phase III clinical report and conditional marketing application materials to the National Center for Drug Evaluation on February 18, and the analysis results of the key data of Phase III clinical trials have also been submitted recently. At present, our original solution production capacity can reach 3.5 billion doses per year, the preparation capacity is 1.5 billion doses per year, and strive to be approved for use at the current critical moment of national epidemic prevention as soon as possible.” Yang Jiaming told reporters.